The impact on medical care from genome-wide association studies (GWAS) can be substantial, laying the groundwork for implementing personalized medicine, based on studies of genetic variation on a population level.
DNA from approximately 72,000 participants from HUNT 2 and HUNT 3 has been genotyped.
The genotyping done in HUNT uses HumanCoreExome from Illumina Inc. This is a genotyping technology that reads about 600,000 genetic variants (genotypes). Using statistical imputation, this set is enriched to around 15 million gene variants that we can use to study associations with health and disease.
The genotyping was performed in its entirety at NTNU Genomic Core Facility, which is located on the site of St. Olav's Hospital in Trondheim. After the genotyping, the data is transferred to HUNT Cloud for storage, quality control and delivery to research projects.
Requests for the use of GWAS data from HUNT must be approved by the K.G. Jebsen Center for Genetic Epidemiology at NTNU. Applications are sent to HUNT, then discussed with the center. The usual approvals from REK and HUNT Research Center will also be required.